Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma (VALFRID)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Valcuria
Information provided by (Responsible Party):
Lund University Hospital
ClinicalTrials.gov Identifier:
NCT01622439
First received: June 12, 2012
Last updated: September 13, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2016
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)